2020
After data collection and distillation of national policies concerning maternal health from 2010 to 2020, 31 national policies were identified meeting the inclusion criteria. Thematic findings include 38 themes (seen in Table 4 ), with most frequent themes including: Expanding funding for maternal health research ( n = 16), Diversifying Healthcare Workforce/Committees ( n = 9), Increasing insurance coverage, training and inclusion of doulas, community birth workers, childbirth educators, lactation consultants and midwives ( n = 9), Expanding Medicaid coverage to 1 year postpartum ( n = 6) and Improving Medical Training for Maternal Health Workers ( n = 6).
Summary of themes in national and Massachusetts state-level bills included in the systematic review.
Expand funding for research on maternal health | 16 | 51.61 | Establish Medicare for All | 11 | 68.75 |
Diversify healthcare workforce | 9 | 29.03 | Inclusion of midwives on maternity care teams | 3 | 18.75 |
Increased insurance coverage, training and inclusion of doulas, community birth workers, and midwives | 9 | 29.03 | Insurance coverage for doula services | 1 | 6.25 |
Expansion of Medicaid coverage to 1 year postpartum | 6 | 19.35 | Formation of a committee/taskforce to reduce racial disparities | 1 | 6.25 |
Improve training of clinical professionals | 6 | 19.35 | |||
Improve data collection | 5 | 16.13 | |||
Implement implicit bias trainings | 5 | 16.13 | |||
Expand telemedicine | 5 | 16.13 | |||
Formation of a committee/taskforce to reduce racial disparities | 5 | 16.13 | |||
Expand funding for research on discrimination and social determinants of health | 5 | 16.13 | |||
Payment Reform | 4 | 12.90 |
Five policies total included in this review were proposed prior to 2018. Three policies were proposed in 2018, 9 policies in 2019, and 14 policies in 2020. Three themes identified in policies were related to the current pandemic, including: Inclusion of Pregnant People in Vaccine Development for COVID19 ( n = 2), Funding for Research in Maternal Health & COVID19 ( n = 2), and Occupation Risk for Pregnant People & COVID-19 ( n = 2). Several themes were related to racial disparities and discrimination, but one theme was identified specific to Black women who give birth: Programs on education, civil rights, and maternal health for Black women and girls ( n = 1).
The themes of the two bills that became law included (1) expanding funding for research on maternal and infant health, (2) improving data collection, and (3) implementing and expanding state Maternal Mortality Review Committees (MMRCs). The themes included in the two bills that only passed the house included: (1) expanding Medicaid coverage to 1 year postpartum, (2) improving coverage of doula services, (3) implementing a bundled payment model, (4) expanding telemedicine, and (5) expanding funding for research on maternal health, specifically in rural communities.
In utilizing a modified version of the analytical framework for evaluating public health policy described in the Methods section, data was extracted from each policy related to effectiveness of the policy, unintended effects of the policy, and health equity . For each of these components, a value of positive, neutral, negative, neutral/positive or neutral/negative was assigned. For evaluation of effectiveness of policies, 19 were identified as having a positive effect (e.g., supporting community-level research or encouraging diversity in committee/ task force bodies), seven identified as neutral/positive (e.g., lacking specificity of insurance expansion, but increasing services generally), and five as having neutral effect (e.g., mentioning grant programs without specifically outlining steps/directives).
For the component of unintended effects, 13 were identified as having neutral unintended effects (e.g., adding various grant programs that may or may not be effective), 13 as positive unintended effects (e.g., insurance expansion & increased access to quality care long-term), and three as having potential negative unintended effects (e.g., policy attempts at increasing diversification of task force membership asking members to serve without additional pay). One policy was classified as neutral/positive unintended effect, and one policy classified as having a neutral/negative unintended effect.
For the component of health equity, 17 policies were identified as having positive impact on health equity (e.g., policy issuing a call for increased research and initiatives to address social determinants of health, and how they affect racial disparities), eight having neutral impact on health equity (e.g., policy briefly mentioning existence of racial and ethnic disparities, but not offering solutions to racial disparities in legislation), and none were identified as having a negative impact on health equity. Four policies were classified as having a neutral/positive impact on health equity, with one policy classified as having a neutral/negative impact on health equity.
From 2010 to 2020, the Massachusetts State Legislature handled 158 bills containing the key terms identified for this review. Of those 158 bills, 16 met inclusion criteria. Massachusetts varied in the number of bills proposed per year across this 10-year period, seen in detail in Table 5 . During this 10-year period, two of those bills passed, while the other 14 remain with the status of being introduced. The bills that passed are (1) An Act Improving the Quality of Health Care and Reducing Costs through Increased Transparency, Efficiency and Innovation, which was signed by the Governor in 2012, and (2) An Act to Reduce Racial Inequities in Maternal Health 4 , which was signed by the Governor on January 13, 2021 ( 24 , 25 ). The distribution in the levels of racism addressed amongst the selected Massachusetts bills are as follows: out of the total 16, one bill addressed only interpersonal racism (5.88%), one bill addressed both interpersonal and institutional racism (5.88%) and the rest addressed only institutional racism ( n = 14, 87.5%). Two bills were identified as “category 2,” predominantly focused on Black maternal health, racial disparities, or health equity. Fourteen bills were identified as “category 1.”
Summary of quality appraisal, status, and category ranking of included Massachusetts state-level bills.
An Act Relative to Medicaid Coverage for Doula Services | 2020 | Introduced | 2 | Positive | Negative | Positive | Interpersonal & Institutional |
An Act to Reduce Racial Inequities in Maternal Health | 2020 | Became law | 2 | Positive | Neutral | Positive | Institutional |
An Act Relative to Out-of-Hospital Birth Access and Safety | 2019 | Introduced | 1 | Positive | Negative | Positive | Interpersonal |
An Act Advancing the Health of Pregnant Persons | 2019 | Introduced | 2 | Positive | Positive | Positive | Institutional |
An Act Establishing Medicare For All in Massachusetts | 2019 | Introduced | 1 | Neutral/Positive | Negative | Positive | Institutional |
An Act Establishing the Honorable Peter V. Kocot Act to Enhance Access to High Quality, Affordable and Transparent Healthcare in the Commonwealth | 2018 | Introduced | 1 | Positive | Positive | Neutral | Institutional |
An Act to Strengthen Behavioral Health Integration | 2017 | Introduced | 1 | Positive | Positive | Neutral/Positive | Institutional |
An Act Establishing Improved Medicare For All in Massachusetts | 2017 | Passed House | 1 | Positive | Positive | Positive | Institutional |
An Act Establishing Medicare For All in Massachusetts | 2015 | Introduced | 1 | Positive | Positive | Positive | Institutional |
An Act to Provide Improved Medicare For All | 2013 | Introduced | 1 | Positive | Positive | Positive | Institutional |
An Act Relative to Certified Professional Midwives | 2013 | Introduced | 1 | Positive | Neutral | Neutral/Positive | Institutional |
An Act Relative to Healthcare Quality Improvement and Cost Reduction Act of 2012 | 2012 | Introduced | 1 | Neutral/Positive | Negative | Positive | Institutional |
An Act Encouraging Nurse Practitioner and Physician Assistant Practice of Primary Care | 2011 | Introduced | 1 | Neutral | Negative | Positive | Institutional |
An Act to Provide Improved Medicare For All | 2011 | Introduced | 1 | Positive | Positive | Positive | Institutional |
An Act to Ensure Quality, Affordability and Access to Primary and Preventive Health Care, to Eliminate Health Disparities, and to Enhance Economic Growth Throughout the Commonwealth | 2011 | Introduced | 1 | Positive | Neutral | Neutral | Institutional |
An Act Improving the Quality of Health Care and Reducing Costs Through Increased Transparency, Efficiency and Innovation | 2011 | Became law | 1 | Neutral | Neutral | Neutral | Institutional |
Sixteen Massachusetts policies were identified meeting the inclusion criteria. Of these, 14 policies were introduced, and two policies became law. Thematic findings include four themes, including: (1) Proposing Medicare for all (ex., mentions covering cost of maternity care/ family planning through perinatal), (2) Supporting midwife involvement on maternity care teams, and (3) Proposing Medicaid coverage for doula services (4) Formation of a committee to reduce maternal racial disparities. Of the two bills that became law the themes included: (1) Forming a committee to reduce maternal racial disparities and (2) expanding access to healthcare.
For evaluation of effectiveness of Massachusetts policies, 12 were identified as having a positive effect (e.g., comprehensively standardizing abortion access and sexual/reproductive health service access for vulnerable populations), two identified as neutral/positive (e.g., legislation containing a myriad of non-maternal health parts, but additionally containing some language around expanding provider accessibility during pregnancy), and two as having neutral effect (e.g., actual implementation of policy impacted by health care context/culture.) For the component of unintended effects, five were identified as having unintended potential negative effects (e.g., allowance of disenrolled providers to continue being able to treat pregnant individuals, potentially allowing providers disenrolled for harmful reasons to work with patients), seven as positive unintended effects (e.g., broad language around maternity and fertility care allowing ability to insert abortion care and access underneath umbrella of coverage), and four as having neutral unintended effects (e.g., attempt to incentivize physicians to leave private practice in favor of CHCs.) For the component of health equity, 11 policies were identified as having positive impact on health equity (e.g., correcting social inequities through increasing representation in legislation), three having neutral impact on health equity (e.g., simple reference to culturally competent providers), and two as having a neutral positive impact on health equity (e.g., containing language noting performance benchmarks for hospitals shall include reduction of racial and ethnic disparities without clarifying disparities and consequences to hospitals that don't abide.) None were identified as having a negative or neutral negative impact on health equity.
This systematic policy review investigated legislation proposed and passed to address Black maternal health in Massachusetts and at the national level from 2010 to 2020. Specifically, we analyzed and compared policies between Massachusetts and the federal government regarding health equity in maternal care and improving Black maternal health to determine what could be implemented on a national level that Massachusetts has proposed. Overall, we found that there is a lack of legislation that would address maternal racial disparities that is passed at both the federal level and in Massachusetts. At the federal level, only two bills were passed out of 31 proposed, and in Massachusetts, only two bills were passed of the 16 proposed. Even still, the bills that have passed (National: PREEMIE Reauthorization Act of 2018 and Preventing Maternal Deaths Act of 2018, Massachusetts: An Act to Reduce Racial Inequities in Maternal Health and An Act Improving the Quality of Health Care and Reducing Costs through Increased Transparency, Efficiency and Innovation 5 ) represent only initial movement toward improving maternal outcomes over time ( 22 – 25 ).
The bills that became law on the national levels sought to address Black maternal health by identifying disparities through improved data collection, including the establishment of maternal mortality review committees (MMRC) across the country and a standardized form, the Maternal Mortality Review Information Application (MMRIA 6 ), through the Centers of Disease Control and Prevention (CDC)'s “Review to Action” program ( Maternal Mortality Review Information Application, MMRIA ). This seeks to standardize the process of reporting and analyzing maternal death across the country to determine preventability, factors that contribute to the deaths, and what areas in particular need to be addressed in a more holistic manner, through the interprofessional MMRC team. Another aspect of the bills that have become law nationally is to allocate funding for research on preterm birth. Expanding funding for research on the topic has been a predominant theme amongst the included national bills.
Additionally, two bills nationally passed the House of Representatives but have not been voted upon in the Senate: The Maternal Health Quality Improvement Act of 2020 7 and The Helping MOMS Act of 2020 8 ( 26 , 27 ). While it is unclear whether these two bills will become law, they address several focuses that have been commonly proposed in other bills that remained stagnant in the House of Representative or Senate.
In Massachusetts, one bill that became law, An Act to Reduce Racial Inequities in Maternal Health, established a diverse commission specifically to examine and make recommendations to reduce racial inequities in maternal health ( 25 ). The other bill that passed into law, An Act Improving the Quality of Health Care and Reducing Costs through Increased Transparency, Efficiency and Innovation, aimed to improve the quality of healthcare and reduce healthcare costs through increased transparency, efficiency, and innovation within the healthcare system ( 24 ). Lastly, the bill that passed the House but has not been passed in the Senate, An Act Establishing Improved Medicare For All in Massachusetts, 9 would enact Medicare for all residents in the state and establish a statewide healthcare trust to disburse funds for medical treatment ( 28 ).
Two of the most salient themes noted across policies were similar at the federal level and in Massachusetts. First, bills identified the need for increased roles and support for doulas and midwives. Although these bills did not directly address Black maternal health, heightening the availability, compensation, and services that doulas and midwives can offer will likely result in healthier outcomes for Black mothers. Previous research demonstrated that Black women experience lower risk for cesarean birth and intrapartum analgesia with the presence of a doula who can provide continual emotional and relational support through birth ( 29 ). Given the substantial association between doula services and labor and delivery outcomes, some states such as Oregon and Minnesota have already expanded Medicaid to support doula services ( 30 ). However, this is yet to be supported on a national level or in Massachusetts. These bills also propose Medicaid expansion for other birth and breastfeeding support roles, such as childbirth educators and lactation consultants. Studies demonstrate that attending childbirth classes reduce labor interventions and risk for cesarean birth ( 31 ). Access to lactation consultants and lactation education has been shown to increase initiation of breastfeeding and likelihood of exclusive breastfeeding, which improves health outcomes such as disease burden for both mother and child ( 32 , 33 ). The bills that were included under this theme addressed two aspects of expanding the roles of doulas, midwives, lactation consultants, and community health workers. The bills both called for greater inclusion of these professions into the birth setting, policy development, MMRCs, and research while also proposing increased access to these professions by expanding insurance coverage, including Medicaid, to cover their services and establishing community-based training and recruitment efforts to increase the workforce numbers and diversity.
Another similar theme for bills at the federal level and in Massachusetts was diversification of committees to address maternal health disparities. Diversifying committees may lead to greater health equity by providing a platform for communities of color to have representation in discussions of maternal health. Federal level bills also proposed further diversifying the healthcare workforce. Studies have shown that a shared racial identity between Black mothers and providers may halve the mortality rate of Black infants ( 34 ).
One other core theme that emerged at the federal level was funding for research expansion. With the recent recognition of Black maternal health as a public health crisis, there may be a temporary surge in funding to investigate racial disparities in healthcare settings. However, for the multipronged societal intervention required to alter the underlying institutional racism that has resulted in maternal racial disparities, long-term funding will be required across many different settings and areas of study. This will include funding to create effective community-level interventions for social determinants of health, such as housing, employment, and other environmental barriers to health equity.
In Massachusetts, there was particular emphasis to enact Medicare for all, which is a single payer health care financing system for all residents. This includes coverage for prenatal, pregnancy, and postpartum services, and would allow for care beyond the current coverage of 60 days postpartum through Medicaid for women who meet poverty level financial thresholds. Medicaid prioritizes coverage for pregnant women and finances over 4 in 10 births in the United States ( 35 ). However, nearly one-third of maternal mortalities occur between 1 week and 1 year postpartum, the majority of whom are Black women ( 5 ). This therefore suggests the need for expansion of Medicaid coverage to 1 year postpartum ( 36 ). States can apply for a waiver to extend postpartum coverage, but only the federal government can alter the length of postpartum coverage. Recently, the Helping MOMS Act of 2020, a bill that proposes lengthening postpartum coverage to 1 year, has passed the House of Representatives and is one of the most common themes identified in 19.4% of bills at the federal level, but has yet to be enacted as law (citepbib700).
Across analyses, both federal and Massachusetts level legislature were determined to have a neutral or positive effect, with most also having positive or neutral unintended effects and a positive impact on health equity. However, it is important to note that because these analyses included legislation that specifically addressed terms related to race and health equity, there may be a difference in unintended effects and health equity between bills included here and others that only mention race in an epidemiological sense. For instance, previous research demonstrates that state-level policies that impact clinic closures and impose restrictions on gestational age for abortion increase mortality rates ( 37 ).
Institutional and/or interpersonal racism were most commonly addressed across federal and Massachusetts policies. Federal policies may be particularly effective in addressing issues of health equity and racism, as federal policies provide a minimum standard to which all states must adhere. For example, if Medicaid were extended to 1 year postpartum at the federal level, racial disparities in maternal mortality may decrease across the population ( 36 ). Although these analyses focus particularly on legislation related to maternal racial disparities, it is essential to also recognize that policies that relate to other aspects of institutional racism (i.e., housing, employment, education) also have the potential to make significant improvement in the health of Black women.
At both the federal level and in Massachusetts, there are still many gaps to be addressed. In particular, postpartum depression within Black, Indigenous and People of Color (BIPOC) populations has yet to be identified as a focus within policy. However, studies suggest that there are great disparities between Black and white women in both diagnosis and treatment for postpartum depression ( 38 ). Black women are less likely than their white counterparts both to attend postpartum appointments that might result in diagnosis of postpartum depression and to attend follow-up appointments to treat postpartum depressive symptoms ( 39 ). Researchers speculate that many factors could be contributing to this outcome, including fear of racial discrimination from healthcare providers, mental health stigmas, and issues of access and practicality related to attending another appointment ( 40 , 41 ). Policies are needed to ensure equitable opportunity and access to diagnostics and follow-up treatment for Black women.
Another important gap to address is funding for hospitals with poor maternal health outcomes. This is especially important in hospitals that serve communities of color and low-income communities. One study showed that location of delivery accounted for 47.7% of racial disparities in severe maternal morbidity rates between Black and white mothers, with Black mothers being more likely to deliver at high-risk hospitals for severe maternal morbidity ( 42 ). By implementing policies that allow for additional funding and resources in hospitals that primarily serve communities of color, we may begin to create more equitable systems for Black women and improve maternal outcomes.
Importantly, most policies aim to address the symptoms of institutional racism rather than the root causes. For instance, institutional racism has made it such that healthcare workers in decision-making roles are predominantly white males ( 43 ). This in turn has resulted in several bills calling for diversity within the healthcare workforce at the national level. Certainly, diversity of healthcare providers may begin to improve patient-provider relationships for Black women, but it does not heal the deep wound and impact of institutional racism entirely. A single bill does not address the inherent racial bias woven into every part of the fabric of the healthcare system and American society that has ultimately manifested in the preventable deaths of Black mothers. Rather, it is clear that many of the symptoms of institutional racism will need to be addressed at the policy level in order to begin to alter the course of action required to reverse trends in maternal racial disparities.
In this systematic review, we compare state-level legislation in Massachusetts to national level legislation addressing maternal health and racial disparities between 2010 and 2020. After accounting for all inclusion criteria, we found that only 31 national and 16 state-level bills were proposed. Of the proposed bills, two federal and two state-level bills were enacted into law. Although there is initial movement toward increasing bills that can focus on and address maternal health disparities, tremendous progress still remains to be seen at both the state and federal level to improve outcomes for Black women.
Author contributions.
The study idea was formulated and written by KC, AK, PM, BM, SA, and EA. Initial analyses were performed by PM, BM, SA, and EA. Final analyses were performed and reported by KC and AK. Final writing and preparation of the manuscript, including edits, were done by KC, AK, and NA-O. All authors contributed to the article and approved the submitted version.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
1 Black Maternal Health Momnibus Act of 2020, no. H.R.6142, 116th Congress (2020).
2 Preventing Maternal Deaths Act of 2018, H.R.1318, 115th Congress (2017-2018), Public Law No: 115-344 (2018). Available online at: https://www.congress.gov/bill/115th-congress/house-bill/1318/text .
3 PREEMIE Reauthorization Act of 2018, S.3029, 115th Congress (2017-2018), Law No: 115-328 (2018). https://www.congress.gov/bill/115th-congress/senate-bill/3029 .
4 An Act to Reduce Racial Inequities in Maternal Health, no. H.4818, 191st Congress of MA (2019-2020) (2021). Available online at: https://malegislature.gov/Bills/191/H4818 .
5 An Act Improving the Quality of Health Care and Reducing Costs through Increased Transparency, Efficiency and Innovation, no. S. 2400, 187th Congress of Ma (2011-2012) (2012). Available online at: https://malegislature.gov/Bills/187/S2400 .
6 Maternal Mortality Review Information Application (MMRIA). Review to Action . Available online at: http://www.mmria.org/ .
7 Maternal Health Quality Improvement Act of 2020, no. H.R. 4995, 116th Congress (2019-2020) (2020). Available online at: https://www.congress.gov/bill/116th-congress/house-bill/4995/text .
8 Helping MOMS Act of 2020, no. H.R. 4996, 116th Congress (2019-2020) (2020). Available online at: https://www.congress.gov/bill/116th-congress/house-bill/4996 .
9 An Act Establishing Improved Medicare For All in Massachusetts, no. H. 2987, 190th Congress of MA (2017-2018) (2018). Available online at: https://malegislature.gov/Bills/190/h2987 .
Selena Simmons-Duffin
After an alarming spike in 2021, maternal mortality numbers the next year went back down, according to a report released Thursday. CDC Director Mandy Cohen says the rates are still too high. Rich Legg/Getty Images hide caption
After an alarming spike in 2021, maternal mortality numbers the next year went back down, according to a report released Thursday. CDC Director Mandy Cohen says the rates are still too high.
After spiking in 2021, the maternal mortality rate in the U.S. improved significantly the following year, according to a new report from the Centers for Disease Control and Prevention.
The data shows that 817 women died of maternal causes in the U.S. in 2022, compared to 1,205 in 2021. These are deaths that take place during pregnancy or within 42 days following delivery, according to the World Health Organization , "from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes."
"I think that the bump [in 2021] reflects the pandemic and we're returning to pre-pandemic levels," says study author Donna Hoyert, who a health scientist at the CDC's National Center for Health Statistics.
The maternal mortality rate in 2022 was 22.3 deaths per 100,000 live births. That's a significant decrease from the 2021 rate of 32.9, but it's still much higher than the rate in other wealthy countries.
There continue to be enormous racial disparities in the U.S. maternal mortality rate as well – the rate for Black women was 49.5 deaths per 100,000 births in 2022, compared to a rate of 19 deaths for white women. Research shows the vast majority of these deaths are preventable .
Dr. Veronica Gillispie-Bell is an OB-GYN in New Orleans who was not involved in the CDC report. She agrees that COVID-19 was likely the reason for the major spike in maternal mortality.
"I really think that 2021 was actually an outlier because of the circumstances," Gillispie-Bell says. "We know that because of COVID-19, there were disruptions to care that obviously impacted our ability to care for pregnant individuals, plus there were pregnant individuals who were dying from COVID." It's hard to know for certain since the CDC report did not include cause of death, she adds.
She's encouraged that the 2022 numbers are slightly lower than 2020 – 817 in 2022 versus 861 in 2020. "It could mean that we're moving in the right direction – I think we need more years of data to know," she says.
CDC's newest data comes several weeks after an academic study cast doubt on the agency's methodology, suggesting that a pregnancy checkbox on death certificates was causing the numbers to be much higher than they are in reality. CDC strongly rejected the study's findings.
Hoyert also defends CDC's methodology. "There was plenty of literature before we made the changes that we were underestimating [maternal deaths] without a checkbox, and so we did add the checkbox," she says, explaining that they have continued to do evaluations and issue guidance to ensure it's being used correctly.
"I think CDC is doing great work in collecting the data and sharing that back," CDC Director Mandy Cohen told NPR last month. "We disagree with how that study was looking at it, and think it's unacceptable for moms to be dying at that rate here in the United States."
The stakes for getting these numbers right are high in a post- Roe America. Reproductive health advocates warn that abortion bans threaten women's lives, and if CDC's data is not viewed as reliable by the public, that could make it hard to evaluate the impact of these restrictions.
In a statement about CDC's latest report, Dr. Verda Hicks, president of the American College of Obstetricians and Gynecologists, connected the maternal mortality figures to "the worsening state of reproductive health care since the Dobbs decision."
"When treating pregnancy complications, abortion care can be lifesaving, and withholding that care unquestionably compromises patient lives and outcomes," Hicks wrote.
Despite the challenges with the data, Dr. Gillispie-Bell says the public should still put a "great bit of stock" into CDC's analysis. She also pointed to the work of state maternal mortality review committees around the country – she is the medical director of the committee in Louisiana. They are supported and funded by CDC.
"The first step for our maternal mortality review committee – once we get the death certificate with that pregnancy checkbox – is to then start extracting data to confirm ... so our numbers are very accurate," she says.
Not all states have these committees validating maternal deaths and making recommendations to reduce their numbers. CDC Director Cohen pointed out the agency now has funding available for each state. She also pointed out that CDC's data has already led to policy changes to reduce maternal deaths, including allowing Medicaid coverage to continue for a year postpartum .
"I think we're making strides, which is great," Cohen added. "We have more work to do."
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Journal of Perinatology ( 2024 ) Cite this article
Metrics details
Neonatal Escherichia coli ( E. coli ) sepsis is increasing. There is limited data on the factors contributing to increased mortality and severity of illness in neonatal E. coli sepsis. A retrospective review of neonates (<30 days) admitted to a Level IV NICU in the United States from 2008 to 2022 diagnosed with E. coli bloodstream or cerebrospinal fluid infection was conducted. Primary outcome was defined as mortality from or severe illness during E. coli infection (defined as a need for inotropic support or metabolic acidosis). E. coli neonatal sepsis rate increased from 2008 to 2022 (average of 1.12 per 1000 live births). The primary outcome, which occurred in 57.4% of cases, was independently associated with prematurity, neutropenia, and thrombocytopenia. Ampicillin resistance was not associated with the primary outcome. GA, neutropenia, and thrombocytopenia but not ampicillin resistance, are associated with mortality or severe illness from E. coli sepsis.
Bacterial etiology and risk factors among newborns suspected of sepsis at hawassa, ethiopia, introduction.
Neonatal bacterial infections have significant morbidity and mortality, with an estimated annual 6.3 million cases and 230,000 deaths globally [ 1 ]. In the United States, the incidence of neonatal bacterial sepsis varies between one and four per 1000 live births (LBs) [ 2 ]. Neonatal sepsis is categorized into early-onset (EOS, infants ≤72 h old) and late-onset sepsis (LOS, infants >72 h). EOS classically represents maternal-to-fetal transmission, while most LOS are nosocomial or community-acquired [ 3 ]. As antenatal Group B Streptococcus (GBS) screening and intrapartum antibiotic prophylaxis (IAP) have led to significantly decreased GBS EOS, Escherichia coli ( E. coli ) is now one of the predominant organisms responsible for EOS [ 4 , 5 , 6 , 7 ]. Within the National Institute of Child Health and Development (NICHD) Neonatal Research Network (NRN) neonatal intensive care units (NICUs), 36.6% of EOS cases are due to E. coli (0.4 per 1000 live births), compared to 30.2% from GBS [ 4 ]. The Centers for Disease Control and Prevention (CDC) Active Bacterial Core surveillance data from 2005 to 2014 reported that 24.8% of EOS (0.2 per 1000 live births) in the US were E. coli infections [ 8 ]. The E. coli fraction of EOS cases increases to 58% (NRN) and 44% (CDC) for very low birth weight (VLBW, <1500 g BW) infants. E. coli is also the leading Gram-negative organism in LOS (5–12%) in preterm infants in the US [ 6 , 9 , 10 ]. E. coli sepsis in neonates is associated with substantial mortality, which is influenced by the gestational age (GA), birth weight (BW), and immune status of the neonate [ 11 , 12 , 13 ].
Although the evaluation of suspected EOS has changed over time, the first-line drugs still remain ampicillin and gentamicin [ 14 ]. There has been growing concern regarding the emergence of multidrug-resistant E. coli strains and reports of increasing resistance to ampicillin and gentamicin [ 15 , 16 , 17 ]. The rates of ampicillin and gentamicin resistance in E. coli isolates from US NICUs were between 66–80% and 8–17%, respectively [ 4 , 18 ]. The use of ineffective empiric antibiotics due to resistance results in inadequate infection control and disease progression to severe illness or death
There are inconsistent reports of an association between the risk of death among infants with E. coli EOS and ampicillin resistance [ 19 ]. It is critical to identify the risk factors associated with mortality and severe illness from E. coli sepsis so that antibiotic stewardship programs and aggressive antibiotic regimens for neonates at risk can coexist in the NICU. We determined specific risk factors associated with mortality or severe illness in E. coli neonatal sepsis.
We conducted a retrospective review of all neonates ≤30 days old with E. coli positive blood or cerebrospinal fluid (CSF) culture admitted to Rainbow Babies and Children’s Hospital, a Level IV NICU in Cleveland, Ohio, from 01/01/2008 through 12/31/2022. This study was approved by the Institutional Review Board, and informed consent was waived due to its retrospective nature. Information was collected on infant and maternal clinical and demographic variables. Infants with congenital anomalies and conditions that would predispose to infection, such as immunodeficiency syndromes, were excluded from statistical analysis. Microbiological information included hours of life at culture collection, source (blood vs CSF), time to positivity, and antibiotic resistance profile. Infant clinical characteristics included outcome (discharged home vs death due to E. coli infection), complete blood counts (CBC) during sepsis, duration of antibiotic therapy, presence of metabolic acidosis (pH <7.20 or base deficit >10 mEq/L without respiratory acidosis) and need for inotropic medication during the E. coli sepsis episode. Maternal characteristics included presence of intra-amniotic infection (IAI, defined as maternal peripartum fever 38–38.9 °C with signs of purulent cervical drainage, maternal leukocytosis, or fetal tachycardia, or isolated maternal fever ≥39 °C), E. coli infection in the mother at any time during pregnancy, and maternal intrapartum antibiotic therapy.
We defined our primary outcome as either death or severe illness from E. coli infection. Death was attributed to E. coli infection if it happened at any point from collection of the blood or CSF culture till the end of antibiotic treatment for that particular episode of infection. Severe illness was defined as the new need for inotropic medication or new development of metabolic acidosis, as described above, during the episode of E. coli infection. We specifically included only those infants in our primary outcome who had a new need for inotropic medication and had worsening or new metabolic acidosis at the time of blood or CSF culture at any time during the treatment of the infection as these clinical findings can exist in preterm neonates for reasons other than bacterial sepsis. The time of detection of sepsis, which was used to differentiate between EOS and LOS, was based on the time of collection of blood or CSF culture relative to the time of birth.
Charts that met inclusion and exclusion criteria were checked for completeness and consistency and coded into Rstudio Version 2023.06.1+524. Descriptive data were obtained, and summary statistics were created. These summary tables included the associated p -value stratified for the variable of interest. The primary outcome variable was death or severe illness, as defined above. For all analyses, this composite outcome was used for descriptive statistics and logistic regression modeling. Two-way ANOVA was used to evaluate the interaction and main effects of two factors on the dataset. The analysis included multiple comparisons to assess differences between both columns and rows. Bivariate analysis was performed to identify co-linearity between variables of interest. Those variables that were strongly associated ( p < 0.05) with the outcome variable and relevant to our study were used. Multivariable logistic regression was performed using a backward stepwise method to identify key variables to improve the model’s overall fit to the dataset. The model fitness was assessed using the goodness of fit test to estimate if the model fits the data appropriately. Odds ratios were identified and represented in an odds ratio plot with a 95% confidence interval. This odds ratio plot was used to identify and assess the direction of association between the predictor variables and the outcome variable. P -values were reported for each of the given variables in the multivariate logistic regression model. The generalized variance inflation factor (GVIF) was used to identify co-linearity between predictor variables numerically. Those variables with GVIF greater than five were excluded from the model despite these parameters adding significance to the model.
In the 59,984 live-born infants from 2008 to 2022, there were 68 unique cases of monomicrobial E. coli bloodstream or CSF infection in neonates under 30 days old (1.12 cases per 1000 LBs). E. coli sepsis incidence per 1000 LBs has steadily increased at our center from 0.35 (7/19,716) in 2008–2012 to 1.03 (21/20 331) in 2013–2017 and to 2.01 (40/19 932) in the last five years (2018–2022) respectively. The incidence of E. coli sepsis in VLBW infants was 12.4 per 1000 LBs. There were 38 cases of EOS and 30 cases of LOS. Median GA and BW of infants with E. coli sepsis were 31 2/7 wks (27 4/7 – 38 0/7 wks) and 1620 g (970–2835 g) respectively. There were three cases of E. coli meningitis; two grew E. coli from their blood cultures simultaneously. The median age of diagnosis of E. coli sepsis was 31.5 h (1.9–173.8 h).
Twenty-one infants (30.8%) were born to mothers with a documented IAI. EOS was significantly higher in these infants vs. LOS ( p < 0.001). Only two E. coli LOS cases (without a previous EOS) occurred in infants born to mothers with IAI. There were no differences between rates of mortality, severity of illness, or the primary outcome between infants who were born to mothers with IAI vs those who were not.
There were 38 EOS and 30 LOS cases during the 15-year study period (Table 3 ). Males were more likely to have LOS than females, who were more likely to have EOS. The median GA or BW was not different between EOS and LOS infants. Although more VLBW infants were in the EOS group than the LOS group (55% vs 33%, p = 0.071), this did not reach statistical significance. There was no difference between ampicillin or gentamicin resistance between EOS and LOS E. coli isolates. Mortality was not different between EOS and LOS cases, and neither was a need for inotropic medication or severe metabolic acidosis.
Thirty-nine (57.4%) infants out of the 68 diagnosed with E. coli sepsis met the primary outcome (Table 2 ). 24/39 (61.5%) of these infants had a BW < 1500 g (VLBW). Out of all VLBW infants diagnosed with E. coli sepsis, 77.4% experienced death or severe illness in comparison to 40.5% in infants with BW ≥ 1500 g who were diagnosed with E. coli sepsis (OR 5.029, 95% CI 1.729–14.624, p = 0.003). The median age (IQR) at which E. coli infection was diagnosed for infants with the primary outcome was 37 h (2–168), with 22/39 (56.4%) of these infants having EOS. Twenty-nine of the 39 infants (74.4%) had ampicillin-resistant E. coli , which was not statistically different from the degree of ampicillin-resistance in the entire cohort (69.1%), or in the infants who survived to discharge without severe E. coli sepsis (62.1%, p = 0.28). Apart from GA (and its surrogate marker, BW), the lowest platelet count and the lowest ANC during the episode of sepsis were the only other variables significantly different between those infants who died or had severe illness from E. coli sepsis vs those who did not in our univariate analysis (Table 3 ). In addition, infants who died or had a severe illness were also more likely to be thrombocytopenic or neutropenic during the episode of sepsis. There was no association between the primary outcome and sex, race, ampicillin or gentamicin resistance, mode of delivery, or maternal IAI. None of the three cases of E. coli meningitis died or had severe illness. The median antibiotic use duration for E. coli sepsis in those infants who survived (with or without severe illness) was 21 days.
In our multivariate logistic regression model, the combination of GA < 37 weeks, neutropenia, and thrombocytopenia had four times greater odds of an infant experiencing mortality or severe illness related to E. coli sepsis. All three of these variables were individually associated with an increased risk of mortality or severe illness (Fig. 1 ). GA and BW were co-linear variables, so BW was not included in the multivariate model. Note that sex was used as a variable to improve the overall degrees of freedom, which increased the r-squared statistic.
OR for platelet count <150,000/µL = 1.95 (1.68–3.46), GA < 37 weeks = 9.11 (4.23–10.75), ANC < 1500/µL = 1.21 (1.13–3.22). GA gestational age.
Platelet counts and ANCs were available on 64/68 infants with E. coli sepsis, out of which 26 infants were thrombocytopenic (<150,000/µL). The lowest platelet count and ANC at any point of time during the entire duration of the sepsis episode was used for analysis. Those who died or had a severe illness were significantly more likely to be thrombocytopenic as compared to those who did not (64% vs. 14%, p < 0.0001), with a lower median platelet count during the episode of sepsis (97 (70–164) vs. 262 (213–294), p < 0.0001, values in 1000/µL).
Those who died or had a severe illness were also significantly more likely to be neutropenic (<1500/µL) as compared to those who did not (33% vs. 14%, p = 0.04). They also had a lower median (IQR) ANC during the episode of sepsis (2.9 (0.9–5.9) vs. 4.0 (2.4–6.2), p = 0.8, values in 1000/µL), although this did not reach statistical significance.
Antibiotic susceptibility data were available for 67 of the 68 E. coli isolates. Ampicillin resistance was 70% overall and similar when including only VLBW infants. Twenty-eight out of 38 (74%) E. coli EOS isolates and 19/29 (66%) LOS isolates were ampicillin-resistant. Three out of 38 (8%) E. coli EOS cases and 2/29 (7%) LOS cases were gentamicin resistant. Ampicillin and gentamicin resistance did not vary over time. There was no significant difference in our primary outcome between ampicillin-resistant and susceptible cases (29/47, 61.7% vs 10/20, 50.0%, p = 0.37). Ampicillin resistance did not differ between VLBW infants and those with BW ≥ 1500 g (22/30, 73% vs. 25/37, 68%, p = 0.91), EOS and LOS cases (28/38, 74% vs. 19/29, 66%, p = 0.36), infants who met primary outcome vs. those who did not (29/39, 74% vs. 18/28, 64%, p = 0.37), and those who died vs. those who survived (12/17, 71% vs 35/50, 70%, p = 0.96).
E. coli neonatal sepsis accounts for a more significant proportion of cases since the widespread adoption of GBS IAP prophylaxis and subsequent reduction in GBS EOS cases [ 4 , 20 ]. This is reflected in our study, where the incidence rate of E. coli sepsis has increased almost three-fold from 2008–2012 to 2018–2022, despite a similar number of births throughout the entire period. We hypothesize this is predominantly attributable to a global increase in E. coli infection in the community, particularly resistant strains [ 21 , 22 ]. This could potentially lead to increased maternal colonization, leading to more EOS cases, and increased nosocomial transmission, leading to more LOS cases. Although the mortality from E. coli disease did not increase in our cohort during this period, the increase in the number of cases is still of concern as the median duration of antibiotic use in infants who survived after E. coli sepsis was 21 days. On further chart review, a significant number of the cases where CSF studies could not be obtained due to infant instability were subjected to 21 days of antibiotics for possible meningitis. This is particularly concerning as recent epidemiologic studies have shown that every day of antibiotic exposure in neonates increases mortality and risk of bronchopulmonary dysplasia [ 23 , 24 ]. In addition, neonatal EOS and LOS may lead to long-term neurodevelopmental impairments in survivors, both in humans and in animal models of disease [ 25 , 26 , 27 ]. This is one of the few studies to report the factors associated with the composite outcome of mortality or severe illness from E. coli sepsis.
In our univariate analysis, the outcomes of mortality, severe illness, or a combination of either were not associated with sex, maternal race, maternal IAI, maternal intrapartum antibiotic use, delivery type, timing of disease onset, and ampicillin resistance. GA, or BW as a surrogate of GA, thrombocytopenia, and neutropenia, were the only variables significantly different in infants who died or had severe illness, both in the univariate analysis and the multivariate logistic regression model. GA and BW are two variables that have been consistently associated with mortality in neonatal sepsis [ 28 , 29 ]. Thrombocytopenia is more common in Gram-negative and fungal neonatal sepsis than Gram-positive sepsis. It is associated with increased odds of mortality, especially in Gram-negative sepsis in VLBW neonates [ 30 , 31 ]. Thrombocytopenia in neonates has been associated with other morbidities, such as IVH and NEC [ 30 , 32 ]. Thrombocytopenia and neutropenia were both significantly associated with mortality or severe illness in our cohort, both in the univariate analysis and the multivariate logistic regression. Intubation and the need for mechanical ventilation have also often been associated with increased mortality in neonatal sepsis. However, we did not include this variable in our analysis as a majority of these were preterm neonates who were on mechanical ventilation due to their lung disease. We did not have information on the episode-related need for intubation or escalation of respiratory support. There were 15 outborn infants in our cohort, and there were no significant differences in any outcomes when excluding them from analyses. These infants were all transferred from hospitals within our hospital’s health system network.
Antibiotic resistance to E. coli strains has been increasing. Although a substantial number of the isolates in our cohort were resistant to ampicillin, our data were similar to recent cohort studies from the NICHD NRN and the CDC, which point to a more than 80% resistance to ampicillin within E. coli strains isolated from neonates [ 4 , 8 ]. Ampicillin resistance did not change over the 15 years we studied. This starkly contrasts with adult studies, where E. coli is the most commonly isolated bacterial pathogen in culture-positive community-onset sepsis, but the rates of ampicillin resistance are lower and in the 40–50% range [ 33 , 34 ]. Based on microbial susceptibility, unit protocols, and drug availability, either cefotaxime, cefepime, or ceftazidime was added to the antibiotic regimens at our center once an isolate was positive for ampicillin-resistant E. coli . Although there was no difference in the time to positivity between E. coli strains isolated from neonates who met the composite primary outcome vs. those who did not, the prompt switching to a targeted antibiotic could reduce the strength of the finding that ampicillin resistance is not associated with mortality or severity of illness.
Antimicrobial resistance was also similar in VLBW and non-VLBW infants, and we did not find any relationship between ampicillin resistance and death, severe illness, or the composite outcome of either in our study. These data are reassuring, especially in the era of multi-drug resistant E. coli , drug shortages, and concern regarding the continued efficacy of ampicillin and gentamicin as first-line empiric antibiotic therapy for EOS in neonates [ 35 ]. Neonates with antibiotic-resistant E. coli sepsis may also require prolonged hospitalization, which increases the risk of exposure to healthcare-associated infections, including other antibiotic-resistant pathogens. Antimicrobial resistance also leads to longer antibiotic duration and the use of multiple antibiotics, which are independently associated with mortality and morbidity in neonates. Our data point toward the hypothesis that antimicrobial resistance and host-pathogen interaction are possibly exclusive of each other. Mortality and severity of illness are a function of bacterial pathogenicity and host susceptibility. Preterm neonates are susceptible hosts in this context due to their immature developing immune system, which has a dysregulated immune response. Bacterial pathogenicity, which is one of the key drivers of the exaggerated immune response in preterm neonates, leads to endotoxin-mediated tissue damage and hypoxia, metabolic acidosis, cardiorespiratory compromise, organ dysfunction, and ultimately death. Our data lends credibility to the recent AAP consensus statement on the continued use of ampicillin and gentamicin for EOS and warrants caution when attributing causes of sepsis-related death to resistant bacteria [ 36 , 37 ]. We did find a trend towards increased ampicillin resistance in the neonates who met the primary outcome; however, we cannot comment on whether this would have reached statistical significance with a larger sample size.
A major strength of this study is the extended study period. The incidence of E. coli neonatal sepsis is relatively low at any major US NICU. Most studies include NRN, CDC, or VON datasets, which do not account for geographic variations in E. coli pathogenicity patterns. We also use a composite outcome of death or severe illness to identify infant and maternal risk factors. As neonatal care becomes better at reducing the outcome of death, there is an increased burden of morbidities in the survivors, and it is critical to include this in studies on sepsis [ 38 , 39 ]. It is reassuring that ampicillin or gentamicin resistance was not associated with the primary outcome in our study. The rates of ampicillin and gentamicin resistance seen in our population are similar to the rates reported by the recent NRN study, and this rate was similar across EOS and LOS cases as well in VLBW infants who were at the highest risk of death or severe illness [ 4 ]. Although this is from a single center, these data suggest that ampicillin and gentamicin remain effective empiric antibiotics for neonatal sepsis.
The main drawback of this study is that this is a single-center experience; thus, the number of E. coli cases is insufficient to draw conclusions that can be applied to other centers. We were also limited as to which clinical, demographic, and microbiological factors we could use for our analyses due to the retrospective nature of this study. The completeness of the documentation of these factors in the medical record primarily determined the factors we chose to study. We acknowledge that there are possibly multiple other complex mechanisms and factors that are associated with increased mortality or severity of illness in neonatal E. coli sepsis. Maternal factors that have been linked to neonatal death from sepsis are prolonged rupture of membranes, chorioamnionitis, preterm delivery, and cesarean delivery [ 40 ]. Neonatal factors that have been consistently shown to be associated with increased odds of mortality are prematurity and low birth weight [ 41 , 42 ]. Other clinical factors such as respiratory compromise, septic shock, Gram-negative infection, lactic acidosis, and thrombocytopenia have been frequently but not consistently implicated in neonatal sepsis-related mortality [ 42 , 43 , 44 , 45 ].
The laboratory system at our institution instituted new microbiological techniques with enhanced antimicrobial inactivation to improve the isolation of microorganisms in 2016. This upgrade might partially account for the increased E. coli incidence in the last five years. We also do not have follow-up data on the surviving infants, so we cannot speculate on their long-term neurodevelopmental outcomes. However, studies show that hypotension and the need for inotropes are associated with neurodevelopmental impairment (NDI) in preterm infants [ 23 , 46 ]. We also do not have data on other Gram-negative pathogens, such as Klebsiella and Pseudomonas , and hence cannot comment on whether there was a similar increase in their incidence during the time period of our study. We also do not have information on the pathogenic strain or phage typing of the E. coli species isolated, as this is not routinely reported in our laboratory system.
This study adds to the current wealth of knowledge of E. coli sepsis in the neonatal population and the relationship between various host and pathogen factors contributing to poor outcomes.
Original data is available upon request from the corresponding author.
Li J, Xiang L, Chen X, Li S, Sun Q, Cheng X, et al. Global, regional, and national burden of neonatal sepsis and other neonatal infections, 1990-2019: findings from the Global Burden of Disease Study 2019. Eur J Pediatr. 2023;182:2335–43.
Article PubMed Google Scholar
Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390:1770–80.
Cortese F, Scicchitano P, Gesualdo M, Filaninno A, De Giorgi E, Schettini F, et al. Early and Late Infections in Newborns: Where Do We Stand? A Review. Pediatr Neonatol. 2016;57:265–73.
Stoll BJ, Puopolo KM, Hansen NI, Sanchez PJ, Bell EF, Carlo WA, et al. Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of Escherichia coli, and the Need for Novel Prevention Strategies. JAMA Pediatr. 2020;174:e200593.
Article PubMed PubMed Central Google Scholar
Baltimore RS, Huie SM, Meek JI, Schuchat A, O’Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics. 2001;108:1094–8.
Article CAS PubMed Google Scholar
Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK Jr., Smith PB, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88:S69–74.
Lukacs SL, Schrag SJ. Clinical sepsis in neonates and young infants, United States, 1988-2006. J Pediatr. 2012;160:960–965 e961.
Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014. Pediatrics. 2016;138:e20162013.
Flannery DD, Edwards EM, Coggins SA, Horbar JD, Puopolo KM. Late-Onset Sepsis Among Very Preterm Infants. Pediatrics. 2022;150:e2022058813.
Greenberg RG, Kandefer S, Do BT, Smith PB, Stoll BJ, Bell EF, et al. Late-onset Sepsis in Extremely Premature Infants: 2000-2011. Pediatr Infect Dis J. 2017;36:774–9.
Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol. 2009;30:585–91.
Article CAS PubMed PubMed Central Google Scholar
De Wit D, Tonon S, Olislagers V, Goriely S, Boutriaux M, Goldman M, et al. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun. 2003;21:277–81.
Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics. 1999;104:1327–33.
Gray JW, Ubhi H, Milner P. Antimicrobial treatment of serious gram-negative infections in newborns. Curr Infect Dis Rep. 2014;16:400.
Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics. 2008;121:689–96.
Didier C, Streicher MP, Chognot D, Campagni R, Schnebelen A, Messer J, et al. Late-onset neonatal infections: incidences and pathogens in the era of antenatal antibiotics. Eur J Pediatr. 2012;171:681–7.
Alarcon A, Pena P, Salas S, Sancha M, Omenaca F. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J. 2004;23:295–9.
Flannery DD, Akinboyo IC, Mukhopadhyay S, Tribble AC, Song L, Chen F, et al. Antibiotic Susceptibility of Escherichia coli Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017. JAMA Pediatr. 2021;175:168–75.
Bergin SP, Thaden JT, Ericson JE, Cross H, Messina J, Clark RH, et al. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy. Pediatr Infect Dis J. 2015;34:933–6.
Miselli F, Cuoghi Costantini R, Creti R, Sforza F, Fanaro S, Ciccia M, et al. Escherichia coli Is Overtaking Group B Streptococcus in Early-Onset Neonatal Sepsis. Microorganisms. 2022;10:1878.
Schlackow I, Stoesser N, Walker AS, Crook DW, Peto TE, Wyllie DH, et al. Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011. J Antimicrob Chemother. 2012;67:1514–24.
Vihta KD, Stoesser N, Llewelyn MJ, Quan TP, Davies T, Fawcett NJ, et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records. Lancet Infect Dis. 2018;18:1138–49.
Doucette SM, Kelly EN, Church PT, Lee S, Shah V, Canadian Neonatal Network I. et al. Association of inotrope use with neurodevelopmental outcomes in infants <29 weeks gestation: a retrospective cohort study. J Matern Fetal Neonatal Med. 2022;35:6044–52.
Flannery DD, Dysart K, Cook A, Greenspan J, Aghai ZH, Jensen EA. Association between early antibiotic exposure and bronchopulmonary dysplasia or death. J Perinatol. 2018;38:1227–34.
Lieblein-Boff JC, McKim DB, Shea DT, Wei P, Deng Z, Sawicki C, et al. Neonatal E. coli infection causes neuro-behavioral deficits associated with hypomyelination and neuronal sequestration of iron. J Neurosci. 2013;33:16334–45.
Mukhopadhyay S, Puopolo KM, Hansen NI, Lorch SA, DeMauro SB, Greenberg RG, et al. Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants. J Pediatr. 2020;221:39–46 e35.
Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004;292:2357–65.
Lukacs SL, Schoendorf KC, Schuchat A. Trends in sepsis-related neonatal mortality in the United States, 1985-1998. Pediatr Infect Dis J. 2004;23:599–603.
Thatrimontrichai A, Premprat N, Janjindamai W, Dissaneevate S, Maneenil G. Risk Factors for 30-Day Mortality in Neonatal Gram-Negative Bacilli Sepsis. Am J Perinatol. 2020;37:689–94.
Ree IMC, Fustolo-Gunnink SF, Bekker V, Fijnvandraat KJ, Steggerda SJ, Lopriore E. Thrombocytopenia in neonatal sepsis: Incidence, severity and risk factors. PLoS One. 2017;12:e0185581.
Levit O, Bhandari V, Li FY, Shabanova V, Gallagher PG, Bizzarro MJ. Clinical and laboratory factors that predict death in very low birth weight infants presenting with late-onset sepsis. Pediatr Infect Dis J. 2014;33:143–6.
Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? Pediatrics. 2003;111:1411–5.
Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA Netw Open. 2020;3:e202899.
Daneman N, Fridman D, Johnstone J, Langford BJ, Lee SM, MacFadden DM, et al. Antimicrobial resistance and mortality following E. coli bacteremia. EClinicalMedicine. 2023;56:101781.
Weissman SJ, Stoll B. Ampicillin and Gentamicin in Infants With Suspected Sepsis: Long Live Amp and Gent-But for How Long? JAMA Pediatr. 2021;175:131–2.
Puopolo KM, Benitz WE, Zaoutis TE, Committee On F, Newborn, Committee On Infectious D. Management of Neonates Born at </=34 6/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. Pediatrics. 2018;142:e20182896.
Puopolo KM, Benitz WE, Zaoutis TE, Committee On F, Newborn, Committee On Infectious D. Management of Neonates Born at >/=35 0/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. Pediatrics. 2018;142:e20182894.
Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015;314:1039–51.
Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129:1019–26.
Iqbal F, Chandra P, Khan AA, Lewis LES, Acharya D, Vandana K, et al. Prediction of mortality among neonates with sepsis in the neonatal intensive care unit: A machine learning approach. Clin Epidemiol Glob Health. 2023;24:101414.
Article CAS Google Scholar
Liang LD, Kotadia N, English L, Kissoon N, Ansermino JM, Kabakyenga J, et al. Predictors of Mortality in Neonates and Infants Hospitalized With Sepsis or Serious Infections in Developing Countries: A Systematic Review. Front Pediatr. 2018;6:277.
Jovicic M, Milosavljevic MN, Folic M, Pavlovic R, Jankovic SM. Predictors of Mortality in Early Neonatal Sepsis: A Single-Center Experience. Medicine. 2023;59:604.
Google Scholar
Chen X, He H, Wei H, Chen F, Hu Y. Risk factors for death caused by early onset sepsis in neonates: a retrospective cohort study. BMC Infect Dis. 2023;23:844.
Vizcarra-Jimenez D, Copaja-Corzo C, Hueda-Zavaleta M, Parihuana-Travezano EG, Gutierrez-Flores M, Rivarola-Hidalgo M, et al. Predictors of Death in Patients with Neonatal Sepsis in a Peruvian Hospital. Trop Med Infect Dis. 2022;7:342.
Muktan D, Singh RR, Bhatta NK, Shah D. Neonatal mortality risk assessment using SNAPPE- II score in a neonatal intensive care unit. BMC Pediatr. 2019;19:279.
Osborn DA, Evans N, Kluckow M, Bowen JR, Rieger I. Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. Pediatrics. 2007;120:372–80.
Download references
These authors contributed equally: Adriana Hoffman, Sriram Satyavolu
Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
Adriana Hoffman, Sindhoosha Malay, Thomas Raffay & Devashis Mukherjee
Case Cardiovascular Research Institute, Cleveland, OH, USA
Sriram Satyavolu
Case Western Reserve University School of Medicine, Cleveland, OH, USA
Danah Muhanna
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Anne Windau & Eric M. Ransom
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
Eric M. Ransom
You can also search for this author in PubMed Google Scholar
AH conducted chart review, data gathering, writing, and manuscript editing. SS conducted statistical analysis and wrote and edited the manuscript. D Muhanna conducted a preliminary literature review and wrote and edited the manuscript. SM conducted statistical analysis. TR performed data gathering and edited the manuscript. AW and ER conducted GA gathering, reviewing, and editing the manuscript. D Mukherjee conducted chart review, statistical analysis, writing, and editing and provided a conceptual framework for the manuscript.
Correspondence to Devashis Mukherjee .
Competing interests.
The authors declare no conflicts of interest.
This study was performed in accordance with the Declaration of Helsinki. The Institutional Review Board at University Hospitals Cleveland Medical Center approved this study (20221171) and waived the need to obtain informed consent from study participants due to its retrospective nature. All methods were performed according to institutional guidelines and regulations.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .
Reprints and permissions
Cite this article.
Hoffman, A., Satyavolu, S., Muhanna, D. et al. Predictors of mortality and severe illness from Escherichia coli sepsis in neonates. J Perinatol (2024). https://doi.org/10.1038/s41372-024-02117-9
Download citation
Received : 20 February 2024
Revised : 03 September 2024
Accepted : 06 September 2024
Published : 12 September 2024
DOI : https://doi.org/10.1038/s41372-024-02117-9
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
IMAGES
COMMENTS
definition. Maternal mortality is rela ted to one's reproduct ive health which has been defined by. the Cairo definition of reproduct ive health as "A state of complete physical, mental and ...
The reduction of maternal mortality and the promotion of maternal health and wellbeing are complex tasks. This Series paper analyses the distal and proximal determinants of maternal health, as well as the exposures, risk factors, and micro-correlates related to maternal mortality. This paper also examines the relationship between these determinants and the gradual shift over time from a ...
A Literature Review. In the U.S. in 2021, there were 32.9 maternal deaths per 100,000 live births.1 In comparison with other developed countries of similar wealth, the U.S. stands out as having one of the highest maternal mortality rates.2.
Although the MMR dropped from 900 deaths per 100,000 live births in the 1900s to 12.7 in 2007, the US rate of MMR has seen a rise over the past several decades. (2) In 2014, complications during pregnancy, childbirth, and the postpartum period ranked as the 6th greatest cause of death among women aged 20 to 34 in the United States. (3) The MMR ...
The Pregnancy Mortality Surveillance System (PMSS), which uses multiple sources of information to identify and confirm maternal deaths, estimated that the maternal mortality rate in the United States was 12.1 in 2018 and 12.3 per 100,000 live births in 2019 (as opposed to the NVSS rates of 17.4 in 2018 and 20.1 per 100,000 live births in 2019 ...
The National Center for Health Statistics reported 658 maternal deaths, 277 late maternal deaths, and 3,791,712 live births in 2018, yielding an maternal mortality rate of 17.4 per 100,000 live births and a late maternal mortality rate of 7.2 per 100,000 live births. 8 There was a strong age-mortality gradient between age 20 and 44 years but no ...
This systematic review was conducted to map the literature on all the existing evidence regarding individual and ecological determinants of maternal mortality in the world and to classify them based on the income level of countries. Such a systematic review had not been conducted before. We conducted an electronic search for primary and review articles using "Maternal Mortality" and ...
A robust global health literature incorporates social determinants of health into models explaining maternal mortality in low and middle-income countries, where the vast burden of maternal deaths occur [10-12].These are aided by maternal death audits and social autopsies, which are questions designed to identify the social, behavioral and health system factors that may have contributed to ...
An estimated 287 000 maternal deaths occured worldwide in 2010, most of which were in low-income and middle-income countries and were avoidable. 1 Reduction of maternal mortality has long been a global health priority and is a target in the UN Millennium Development Goals (MDG) framework 2 and a key concern of the Global Strategy for Women's ...
Reducing maternal mortality and morbidity are among the key international development goals. A prerequisite for monitoring the progress towards attainment of these goals is accurate assessment of the levels of mortality and morbidity. In order to contribute to mapping the global burden of reproductive ill-health, we are conducting a systematic review of incidence and prevalence of maternal ...
Introduction. Reducing maternal mortality is one of the priority goals on the international agenda—the new global target is to reduce the maternal mortality ratio (MMR) to <70 maternal deaths per 100 000 live births and country should reduce their MMR by at least two-thirds from the 2010 baseline and no country should have an MMR higher than 140 deaths per 100 000 live births by 2030. 1, 2 A ...
The document is a literature review on maternal mortality in the United States, focusing on trends, disparities, measurement issues, data quality, and monitoring systems. It also discusses how different indicators and definitions impact the understanding of maternal mortality in the country.
Although women of all backgrounds may be at risk, poverty is linked to the higher rates of maternal deaths.4 Most heartbreaking is the CDC's conclusion that six of every 10 maternal deaths that occur can be prevented. Bluntly stated, with better and more accessible health care for all, many would be alive today.
We did a systematic review and meta-analysis of studies on the effects of the pandemic on maternal, fetal, and neonatal outcomes. We searched MEDLINE and Embase in accordance with PRISMA guidelines, from Jan 1, 2020, to Jan 8, 2021, for case-control studies, cohort studies, and brief reports comparing maternal and perinatal mortality, maternal morbidity, pregnancy complications, and ...
Purpose of review: Maternal mortality has recently been featured in both lay and professional literature often with a high degree of passion. This review will provide the obstetrician with a background of the current issues with maternal mortality. Recent findings: Current international data suggest significant improvement in maternal mortality in most countries with the exception of the ...
Objectives. To better understand racial and ethnic disparities in US maternal mortality. Methods. We analyzed 2016-2017 vital statistics mortality data with cause-of-death literals (actual words written on the death certificate) added. We created a subset of confirmed maternal deaths that had pregnancy mentions in the cause-of-death literals. Primary cause of death was identified and recoded ...
A disproportionately high rate of maternal deaths is reported in developing and underdeveloped regions of the world. Much of this is associated with social and cultural factors, which form barriers to women utilizing appropriate maternal healthcare. A huge body of research is available on maternal mortality in developing countries. Nevertheless, there is a lack of literature on the socio ...
Secondly, we systematically review the characteristics and quality of the papers on the macrostructural determinants of maternal mortality. In view of their burden, obstructed labour, unsafe abortion and haemorrhage are proportionally underrepresented in the scientific literature. In our review, most studies analysed were cross-sectional, and ...
It is a literature review for Maternal Mortality. Discover the world's research. 25+ million members; 160+ million publication pages; 2.3+ billion citations; Join for free. Public Full-text 1.
Preeclampsia (PE) is one of the leading causes of preterm birth, direct maternal morbidity, and mortality [], affecting 8 to 10% of pregnancies around the world [].This overwhelming percentage of preeclamptic pregnancies has significantly increased the burden on the economy, clinicians, and healthcare systems [3, 4].There exist disparities in preeclampsia outcomes between low- and high-income ...
Introduction In remote communities, maternal and child health is often compromised due to limited access to healthcare. Simultaneously, these communities historically rely greatly on traditional birth attendants (TBAs). However, optimal integration of these traditional methods with modern healthcare practices remains a topic of debate. We assessed the effect of maternal and child health ...
Background: Black women in the United States experience maternal mortality three to four times more often than white women (1, 2).States vary in degree of disparity, partially due to programs and policies available to pregnant people. In Massachusetts, Black women were approximately twice as likely as white women to experience pregnancy-associated mortality, with a large percentage of these ...
The maternal mortality rate in 2022 was 22.3 deaths per 100,000 live births. That's a significant decrease from the 2021 rate of 32.9, but it's still much higher than the rate in other wealthy countries.. There continue to be enormous racial disparities in the U.S. maternal mortality rate as well - the rate for Black women was 49.5 deaths per 100,000 births in 2022, compared to a rate of 19 ...
The ninth meeting of the Strategic and Technical Advisory Group of Experts (STAGE) for maternal, newborn, child and adolescent health and nutrition was held online on 12-14 May 2024. The meeting agenda included sessions for STAGE guidance or recommendations on the integrated maternal newborn stillbirth programmatic transition framework, the risk differentiated approach to reduce child ...
A starting point is the Data to Save Moms Act (S1599/HR3320), which would strengthen data collection and research on maternal morbidity and mortality among Black and Indigenous populations by ...
A retrospective review of neonates (<30 days) admitted to a Level IV NICU in the United States from 2008 to 2022 diagnosed with E. coli bloodstream or cerebrospinal fluid infection was conducted.